[
    [
        {
            "time": "",
            "original_text": "贝达药业KRAST抑制剂BPI-421286项目I期临床研究首例受试者入组",
            "features": {
                "keywords": [
                    "贝达药业",
                    "KRAST抑制剂",
                    "BPI-421286",
                    "I期临床研究",
                    "首例受试者入组"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业KRAST抑制剂BPI-421286项目I期临床研究首例受试者入组",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]